<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Puretech Health Plc — News on 6ix</title>
<link>https://6ix.com/company/puretech-health-plc</link>
<description>Latest news and press releases for Puretech Health Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/puretech-health-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835eb1678dffbe2df12a837.webp</url>
<title>Puretech Health Plc</title>
<link>https://6ix.com/company/puretech-health-plc</link>
</image>
<item>
<title>PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange</title>
<link>https://6ix.com/company/puretech-health-plc/news/puretech-announces-intention-to-voluntarily-delist-american-depositary-shares-from-nasdaq-and-concentrate-trading-on-the-london-stock-exchange</link>
<guid isPermaLink="true">https://6ix.com/company/puretech-health-plc/news/puretech-announces-intention-to-voluntarily-delist-american-depositary-shares-from-nasdaq-and-concentrate-trading-on-the-london-stock-exchange</guid>
<pubDate>Wed, 29 Apr 2026 06:00:00 GMT</pubDate>
<description>BOSTON, April 29, 2026--PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange</description>
</item>
<item>
<title>PRTC's Seaport Adds Neuropsychiatry Veteran to BOD</title>
<link>https://6ix.com/company/puretech-health-plc/news/prtcs-seaport-adds-neuropsychiatry-veteran-to-bod</link>
<guid isPermaLink="true">https://6ix.com/company/puretech-health-plc/news/prtcs-seaport-adds-neuropsychiatry-veteran-to-bod</guid>
<pubDate>Mon, 27 Apr 2026 11:05:00 GMT</pubDate>
<description>PureTech Health plc announced that its founded entity, Seaport Therapeutics, has appointed Dr. Sharon Mates to its Board of Directors. Dr. Mates, who co-founded and led Intra-Cellular Therapies until its $14.6 billion acquisition by Johnson & Johnson in 2025, brings extensive experience in neuropsychiatry and guiding companies through commercialization and strategic transactions. Her appointment is expected to significantly support Seaport's mission to develop treatments for neuropsychiatric dis</description>
</item>
<item>
<title>PRTC's Gallop: Positive Ph1 Topline MDS & AML Data</title>
<link>https://6ix.com/company/puretech-health-plc/news/prtcs-gallop-positive-ph1-topline-mds-and-aml-data</link>
<guid isPermaLink="true">https://6ix.com/company/puretech-health-plc/news/prtcs-gallop-positive-ph1-topline-mds-and-aml-data</guid>
<pubDate>Wed, 22 Apr 2026 11:00:00 GMT</pubDate>
<description>PureTech Health plc announced positive topline data from its Phase 1b trial of LYT-200 in relapsed/refractory high-risk myelodysplastic syndrome (MDS) and relapsed/refractory acute myeloid leukemia (AML). The trial demonstrated complete responses and a favorable safety profile across both patient groups, with Gallop Oncology selecting a recommended Phase 2 dose and planning to engage with the FDA to discuss a registration-enabling trial for LYT-200 in R/R HR-MDS. In R/R HR-MDS patients treated w</description>
</item>
<item>
<title>PRTC's Seaport Files for Proposed Nasdaq IPO</title>
<link>https://6ix.com/company/puretech-health-plc/news/prtcs-seaport-files-for-proposed-nasdaq-ipo</link>
<guid isPermaLink="true">https://6ix.com/company/puretech-health-plc/news/prtcs-seaport-files-for-proposed-nasdaq-ipo</guid>
<pubDate>Mon, 13 Apr 2026 06:00:00 GMT</pubDate>
<description>PureTech Health plc announced that its founded entity, Seaport Therapeutics, Inc., has filed a registration statement with the SEC for a proposed initial public offering of common stock. The timing, number of shares, and price range for the offering are yet to be determined and are subject to market conditions. This development could potentially impact PureTech Health's valuation as it signals a step towards Seaport's independent public trading.
Disclaimer*</description>
</item>
<item>
<title>PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine</title>
<link>https://6ix.com/company/puretech-health-plc/news/puretech-announces-publication-of-phase-2b-elevate-ipf-trial-results-in-the-american-journal-of-respiratory-and-critical-care-medicine-76</link>
<guid isPermaLink="true">https://6ix.com/company/puretech-health-plc/news/puretech-announces-publication-of-phase-2b-elevate-ipf-trial-results-in-the-american-journal-of-respiratory-and-critical-care-medicine-76</guid>
<pubDate>Thu, 02 Apr 2026 12:19:00 GMT</pubDate>
<description>BOSTON, April 02, 2026--PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine</description>
</item>
<item>
<title>PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers</title>
<link>https://6ix.com/company/puretech-health-plc/news/puretech-founded-entity-seaport-therapeutics-announces-positive-proof-of-concept-topline-results-from-ongoing-phase-1-trial-of-glyphagotm-in-healthy-volunteers-4</link>
<guid isPermaLink="true">https://6ix.com/company/puretech-health-plc/news/puretech-founded-entity-seaport-therapeutics-announces-positive-proof-of-concept-topline-results-from-ongoing-phase-1-trial-of-glyphagotm-in-healthy-volunteers-4</guid>
<pubDate>Thu, 02 Apr 2026 11:08:00 GMT</pubDate>
<description>BOSTON, April 02, 2026--PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo</description>
</item>
<item>
<title>PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans</title>
<link>https://6ix.com/company/puretech-health-plc/news/puretech-founded-entity-seaport-therapeutics-announces-publication-in-science-translational-medicine-featuring-glyphallotm-spt-300-as-the-first-triglyceride-mimetic-prodrug-to-achieve-therapeutically-relevant-drug-levels-in-humans</link>
<guid isPermaLink="true">https://6ix.com/company/puretech-health-plc/news/puretech-founded-entity-seaport-therapeutics-announces-publication-in-science-translational-medicine-featuring-glyphallotm-spt-300-as-the-first-triglyceride-mimetic-prodrug-to-achieve-therapeutically-relevant-drug-levels-in-humans</guid>
<pubDate>Wed, 25 Mar 2026 18:04:00 GMT</pubDate>
<description>BOSTON, March 25, 2026--PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo (SPT-300)</description>
</item>
<item>
<title>PRTC’s Seaport: GlyphAllo Paper Published</title>
<link>https://6ix.com/company/puretech-health-plc/news/prtcs-seaport-glyphallo-paper-published</link>
<guid isPermaLink="true">https://6ix.com/company/puretech-health-plc/news/prtcs-seaport-glyphallo-paper-published</guid>
<pubDate>Wed, 25 Mar 2026 18:00:00 GMT</pubDate>
<description>PureTech Health plc announced that its Founded Entity, Seaport Therapeutics, has published first-in-human clinical and preclinical data for GlyphAllo™ (SPT-300) in Science Translational Medicine, demonstrating it as the first triglyceride-mimetic prodrug to achieve therapeutically relevant drug levels in humans. The publication details the Glyph platform's ability to enable oral dosing and supports the ongoing Phase 2b clinical trial of GlyphAllo for major depressive disorder. Phase 1 trials sho</description>
</item>
<item>
<title>PDMR Notification RSU Vesting</title>
<link>https://6ix.com/company/puretech-health-plc/news/pdmr-notification-rsu-vesting</link>
<guid isPermaLink="true">https://6ix.com/company/puretech-health-plc/news/pdmr-notification-rsu-vesting</guid>
<pubDate>Fri, 13 Mar 2026 16:35:00 GMT</pubDate>
<description>PureTech Health plc announced that a person discharging managerial responsibilities, Eric Elenko, received 112,509 ordinary shares on March 12, 2026, following the vesting of restricted share units granted on May 22, 2023. The shares were issued at a price of 0.01 GBP each, based on an average closing price of 123.67 pence per share over the three trading days prior to the vesting date of March 11, 2026. After this issuance, the company's total issued ordinary share capital stands at 257,927,489</description>
</item>
<item>
<title>Total Voting Rights</title>
<link>https://6ix.com/company/puretech-health-plc/news/total-voting-rights-501</link>
<guid isPermaLink="true">https://6ix.com/company/puretech-health-plc/news/total-voting-rights-501</guid>
<pubDate>Mon, 02 Mar 2026 07:00:00 GMT</pubDate>
<description>PureTech Health plc has announced its total voting rights and share capital as of 28 February 2026. The company's issued share capital consists of 257,927,489 Ordinary Shares, with 16,118,451 shares held in treasury, resulting in a total of 241,809,038 voting rights. This disclosure is intended to assist shareholders in determining their notification obligations under the FCA's Disclosure Guidance and Transparency Rules.
Disclaimer*</description>
</item>
<item>
<title>PRTC to Present at Leerink Healthcare Conference</title>
<link>https://6ix.com/company/puretech-health-plc/news/prtc-to-present-at-leerink-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/puretech-health-plc/news/prtc-to-present-at-leerink-healthcare-conference</guid>
<pubDate>Wed, 25 Feb 2026 07:00:00 GMT</pubDate>
<description>PureTech Health plc announced that its Chief Executive Officer, Robert Lyne, and President, Eric Elenko, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026, at 11:20am EDT, with a webcast available on the company's investor relations website.
Disclaimer*</description>
</item>
<item>
<title>PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis</title>
<link>https://6ix.com/company/puretech-health-plc/news/puretech-announces-orphan-drug-designations-granted-by-the-us-food-and-drug-administration-and-european-commission-for-deupirfenidone-lyt-100-in-idiopathic-pulmonary-fibrosis</link>
<guid isPermaLink="true">https://6ix.com/company/puretech-health-plc/news/puretech-announces-orphan-drug-designations-granted-by-the-us-food-and-drug-administration-and-european-commission-for-deupirfenidone-lyt-100-in-idiopathic-pulmonary-fibrosis</guid>
<pubDate>Thu, 19 Feb 2026 17:36:00 GMT</pubDate>
<description>BOSTON, February 19, 2026--PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone in IPF</description>
</item>
<item>
<title>PRTC's Deupirfenidone Granted FDA & EU ODD for IPF</title>
<link>https://6ix.com/company/puretech-health-plc/news/prtcs-deupirfenidone-granted-fda-and-eu-odd-for-ipf</link>
<guid isPermaLink="true">https://6ix.com/company/puretech-health-plc/news/prtcs-deupirfenidone-granted-fda-and-eu-odd-for-ipf</guid>
<pubDate>Thu, 19 Feb 2026 17:15:00 GMT</pubDate>
<description>PureTech Health plc announced that its deupirfenidone (LYT-100) has received Orphan Drug Designation from both the U.S. Food and Drug Administration and the European Commission for the treatment of idiopathic pulmonary fibrosis (IPF). This designation, granted to the drug being advanced by PureTech's Founded Entity Celea Therapeutics, provides market exclusivity and development incentives for treating this rare and progressive lung disease. Phase 2b trial data showed deupirfenidone 825 mg three </description>
</item>
<item>
<title>PureTech to Present at the JP Morgan Conference</title>
<link>https://6ix.com/company/puretech-health-plc/news/puretech-to-present-at-the-jp-morgan-conference</link>
<guid isPermaLink="true">https://6ix.com/company/puretech-health-plc/news/puretech-to-present-at-the-jp-morgan-conference</guid>
<pubDate>Tue, 06 Jan 2026 12:00:00 GMT</pubDate>
<description>PureTech Health plc announced that its Chief Executive Officer will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 4:30pm PST. A webcast of the presentation will be available on the company's investor relations website. The company, a biotherapeutics firm, aims to transform innovation into value through a capital-efficient R&D model, having already achieved three U.S. FDA approvals.
Disclaimer*</description>
</item>
<item>
<title>PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/puretech-health-plc/news/puretech-present-44th-annual-j-120000136</link>
<guid isPermaLink="true">https://6ix.com/company/puretech-health-plc/news/puretech-present-44th-annual-j-120000136</guid>
<pubDate>Tue, 06 Jan 2026 12:00:00 GMT</pubDate>
<description>BOSTON, January 06, 2026--PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference</description>
</item>
<item>
<title>PureTech Appoints Robert Lyne as Chief Executive Officer</title>
<link>https://6ix.com/company/puretech-health-plc/news/puretech-appoints-robert-lyne-as-chief-executive-officer</link>
<guid isPermaLink="true">https://6ix.com/company/puretech-health-plc/news/puretech-appoints-robert-lyne-as-chief-executive-officer</guid>
<pubDate>Thu, 18 Dec 2025 07:00:00 GMT</pubDate>
<description>BOSTON, December 18, 2025--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announces that the Board of Directors has appointed Robert Lyne as Chief Executive Officer (CEO), and as a member of the Board of Directors, effective immediately.</description>
</item>
<item>
<title>PureTech Appoints Robert Lyne as CEO</title>
<link>https://6ix.com/company/puretech-health-plc/news/puretech-appoints-robert-lyne-as-ceo</link>
<guid isPermaLink="true">https://6ix.com/company/puretech-health-plc/news/puretech-appoints-robert-lyne-as-ceo</guid>
<pubDate>Thu, 18 Dec 2025 07:00:00 GMT</pubDate>
<description>PureTech Health plc has appointed Robert Lyne as Chief Executive Officer, effective immediately, following his tenure as Interim CEO since July 2025. The company's immediate focus is on securing funding for its new entity, Celea Therapeutics, with an expected close in the first half of 2026, after which PureTech's operational run rate will significantly reduce. Concurrently, PureTech is pursuing financing for Gallop Oncology in 2026. The company plans to operate with a streamlined structure and </description>
</item>
<item>
<title>Results of AGM on June 16, 2025 – Update Statement</title>
<link>https://6ix.com/company/puretech-health-plc/news/results-of-agm-on-june-16-2025-update-statement</link>
<guid isPermaLink="true">https://6ix.com/company/puretech-health-plc/news/results-of-agm-on-june-16-2025-update-statement</guid>
<pubDate>Wed, 10 Dec 2025 17:41:00 GMT</pubDate>
<description>PureTech Health plc has provided an update following its June 16, 2025, Annual General Meeting, noting that while all resolutions passed, over 20% of votes opposed Resolutions 2 and 9, concerning the Directors' Remuneration Report and the re-election of Ms. Mazumdar-Shaw. The company engaged with shareholders representing nearly 50% of issued share capital, who advised focusing on UK remuneration principles despite US operational challenges. The Remuneration Committee has reviewed practices, inc</description>
</item>
<item>
<title>Holding(s) in Company</title>
<link>https://6ix.com/company/puretech-health-plc/news/holdings-in-company-865</link>
<guid isPermaLink="true">https://6ix.com/company/puretech-health-plc/news/holdings-in-company-865</guid>
<pubDate>Wed, 10 Dec 2025 17:30:00 GMT</pubDate>
<description>Baillie Gifford & Co has reduced its holding in PureTech Health PLC, with its total voting rights now standing at 4.81%, down from a previous notification of 5.28%. This change, which occurred on December 8, 2025, resulted in Baillie Gifford & Co holding 11,625,873 voting rights, a decrease from 12,529,837. The notification indicates an acquisition or disposal of voting rights, with no financial instruments involved.
Disclaimer*</description>
</item>
<item>
<title>PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis</title>
<link>https://6ix.com/company/puretech-health-plc/news/puretech-announces-successful-end-of-phase-2-meeting-with-fda-for-deupirfenidone-lyt-100-in-idiopathic-pulmonary-fibrosis</link>
<guid isPermaLink="true">https://6ix.com/company/puretech-health-plc/news/puretech-announces-successful-end-of-phase-2-meeting-with-fda-for-deupirfenidone-lyt-100-in-idiopathic-pulmonary-fibrosis</guid>
<pubDate>Mon, 08 Dec 2025 07:00:00 GMT</pubDate>
<description>BOSTON, December 08, 2025--PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis</description>
</item>
</channel>
</rss>